Brokerages Set Pediatrix Medical Group, Inc. (NYSE:MD) Target Price at $10.30

Pediatrix Medical Group, Inc. (NYSE:MD) has earned an average rating of “Hold” from the four brokerages that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $10.30.

MD has been the topic of several research analyst reports. Jefferies Financial Group lowered their price objective on Pediatrix Medical Group from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Wednesday, March 6th. Truist Financial decreased their target price on Pediatrix Medical Group from $10.50 to $10.00 and set a “hold” rating on the stock in a research report on Wednesday, February 21st. Mizuho decreased their target price on Pediatrix Medical Group from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 21st. Finally, TheStreet downgraded Pediatrix Medical Group from a “c” rating to a “d” rating in a research report on Friday, February 23rd.

Pediatrix Medical Group Stock Up 1.6 %

Pediatrix Medical Group stock opened at $9.01 on Thursday. The firm has a market cap of $757.11 million, a price-to-earnings ratio of -12.45, a PEG ratio of 2.44 and a beta of 1.58. The stock has a fifty day simple moving average of $9.20 and a two-hundred day simple moving average of $9.52. Pediatrix Medical Group has a 12 month low of $7.70 and a 12 month high of $15.06. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 0.73.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Tuesday, February 20th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.30 by $0.02. Pediatrix Medical Group had a positive return on equity of 10.35% and a negative net margin of 3.03%. The company had revenue of $496.44 million during the quarter, compared to analyst estimates of $524.30 million. During the same quarter in the previous year, the company posted $0.46 earnings per share. Pediatrix Medical Group’s revenue was down 3.4% compared to the same quarter last year. Equities analysts predict that Pediatrix Medical Group will post 1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in Pediatrix Medical Group by 79.2% in the first quarter. BNP Paribas Financial Markets now owns 41,728 shares of the company’s stock worth $419,000 after purchasing an additional 18,438 shares in the last quarter. Principal Financial Group Inc. grew its stake in Pediatrix Medical Group by 1.1% in the first quarter. Principal Financial Group Inc. now owns 466,487 shares of the company’s stock worth $4,679,000 after purchasing an additional 5,265 shares in the last quarter. Invenomic Capital Management LP grew its stake in Pediatrix Medical Group by 93.3% in the fourth quarter. Invenomic Capital Management LP now owns 1,377,951 shares of the company’s stock worth $12,815,000 after purchasing an additional 664,955 shares in the last quarter. Aristides Capital LLC purchased a new stake in Pediatrix Medical Group during the fourth quarter worth $246,000. Finally, Campbell & CO Investment Adviser LLC lifted its holdings in Pediatrix Medical Group by 334.9% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 96,163 shares of the company’s stock worth $894,000 after buying an additional 74,049 shares during the period. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.